If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Secondary Hyperparathyroidism

Novel Formulation Corrects Vitamin D, Lowers iPTH

Jody A. Charnow May 13, 2012

NATIONAL HARBOR, Md.—An investigational treatment safely and effectively lowers elevated plasma intact parathyroid hormone (iPTH) levels in patients with stage 3 or 4 chronic kidney disease and vitamin D deficiency, researchers reported at the National Kidney Foundation 2012 Spring Clinical Meetings.

High, Low PTH Raises Hypercalcemia Risk

Jody A. Charnow May 13, 2012

NATIONAL HARBOR, Md.—Low and high levels of parathyroid hormone (PTH) are associated with hypercalcemia, according to a study of 106,760 hemodialysis patients presented at the National Kidney Foundation 2012 Spring Clinical Meetings suggest.

SHPT Linked to Vitamin D Deficiency in CKD Patients

Jody A. Charnow May 12, 2012

NATIONAL HARBOR, Md.—Vitamin D deficiency is strongly associated with secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), according to data presented at the National Kidney Foundation (NKF) 2012 Spring Clinical Meetings.

Labs May Vary in iPTH Measurements

Jody A. Charnow May 12, 2012

NATIONAL HARBOR, Md.—Laboratories can differ in their measurements of intact parathyroid hormone (iPTH) levels, resulting in varying treatment approaches for hemodialysis (HD) patients depending on the iPTH assay used, researchers reported at the National Kidney Foundation Spring Clinical Meetings.

CKD Patients May Need Higher 25D Levels

Jody A. Charnow May 11, 2012

NATIONAL HARBOR, Md.—Levels of 25-hydroxyvitamin D (25D) higher than 20 ng/mL would be required to normalize intact parathyroid hormone (iPTH) in patients with stages 3 and 4 chronic kidney disease (CKD) with vitamin D insufficiency and secondary hyperparathyroidism, researchers concluded in a study presented at the National Kidney Foundation 2012 Spring Clinical Meetings.

Calcitriol as Effective as Vitamin D Analogues, but Cheaper

Jody A. Charnow May 11, 2012

NATIONAL HARBOR, Md.—Oral calcitriol is as effective as vitamin D analogues for treating secondary hyperparathyroidism (SHPT) in hemodialysis patients but is more cost effective, according to a study presented at the National Kidney Foundation 2012 Spring Clinical Meetings.

Paricalcitol Superior for Lowering iPTH

Daniel M. Keller, PhD July 18, 2011

The drug was more likely than cinacalcet to achieve a 50 percent or greater decrease in iPTH from baseline.

Antioxidant Nutraceutical May Help Treat Secondary Hyperparathyroidism

Jody A. Charnow April 30, 2011

LAS VEGAS—A novel multivitamin antioxidant nutraceutical may be useful in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients, according to data reported at the National Kidney Foundation's Spring Clinical Meetings.

Inpatient Savings May Offset Cinacalcet Costs

Jody A. Charnow April 29, 2011

LAS VEGAS—Inpatient cost savings may offset the costs of patient adherence to cinacalcet therapy, according to study findings presented at the National Kidney Foundation's Spring Clinical Meetings.

Paricalcitol Found Better for Lowering PTH

Jody A. Charnow April 09, 2011

VANCOUVER, B.C.—Paricalcitol is more effective than ergocalciferol at lowering parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD) stages 3 and 4 and who have vitamin D deficiency and secondary hyperparathyroidism, data suggest.

Cinacalcet May Reduce ESA Use

Jody A. Charnow February 23, 2011

PHOENIX—Cinacalcet hydrochloride (CH) treatment in dialysis patients with secondary hyperparathyroidism may improve responsiveness to an erythropoiesis-stimulating agent (ESA) by reducing systemic inflammation, resulting in decreased ESA requirements, new data suggest.

FGF-23 Linked to Cinacalcet Use

John Schieszer November 20, 2010

Fibroblast growth factor 23 (FGF-23) is positively associated with cinacalcet use, calcium, and phosphorus in hemodialysis (HD) patients, according to a study presented at Renal Week 2010 in Denver.

SHPT in Dialysis Patients Associated with Greater Mortality, Morbidity

John Schieszer November 20, 2010

New data presented at Renal Week 2010 in Denver confirm the high morbidity and mortality associated with secondary hyperparathyroidism (SHPT) in dialysis patients, emphasizing the need for early referral as well as other therapeutic interventions.

Oral Paricalcitol May Have Similar Efficacy to Oral Calcitriol

John Schieszer November 20, 2010

Oral paricalcitol (OP) appears to have similar efficacy and safety compared with oral calcitriol (OC) in dialysis patients with secondary hyperparathyroidism (SHPT), according to results from a randomized, controlled trial presented at Renal Week 2010 in Denver.

Cinacalcet for SHPT Safe, Effective in Renal Transplant Recipients

John Schieszer November 20, 2010

Cinacalcet is a safe and effective option for treating hypocalcemia and secondary hyperparathyroidism (SHPT) in renal transplant recipients, according to a new German study presented at Renal Week 2010 in Denver.

Elevated PTH May Increase Short-Term Mortality Risk in CKD Patients

John Schieszer November 19, 2010

Higher parathyroid hormone (PTH) levels are associated with an increased risk of death, possibly because of a higher prevalence of metabolic syndrome as well as other possible pathways according to a study presented at Renal Week 2010 in Denver.

Cinacalcet May Reduce Mortality in HD Patients with SHPT

John Schieszer November 19, 2010

Cinacalcet may help reduce mortality in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) in the "real world," Japanese researchers reported at Renal Week 2010 in Denver.

Cinacalcet Shows Promise for SHPT in Peritoneal Dialysis Patients

John Schieszer November 18, 2010

Cinacalcet appears to be safe and effective for long-term use in the treatment of secondary hyperparathyroidism (SHPT) in peritoneal dialysis (PD) patients, according to a new study presented at Renal Week 2010 in Denver.

Post-Transplant Cinacalcet May Be An Option

Jody A. Charnow November 02, 2010

Cinacalcet may be useful for treating hyperparathyroidism after renal transplantation, new findings suggest.

Study Examines Impact of Ergocalciferol on Markers of Bone and Mineral Metabolism

John Schieszer June 18, 2010

Weekly (50,000 units) and monthly doses (50,000 units) of ergocalciferol treatment does not significantly impact markers of mineral metabolism (MM) in chronic hemodialysis (HD) patients, a study suggests.

Thrice-Weekly Post-Dialysis Cinacalcet A Viable Option

John Schieszer June 18, 2010

New approach may ease problems with noncompliance, according to researchers.

SHPT Treatment May Have CAC Benefit

John Schieszer June 10, 2010

Cinacalcet plus low-dose vitamin D for secondary hyperparathyroidism yielded encouraging results

Polycystic Kidney Disease Affects PTH-Related Mortality

John Schieszer April 17, 2010

Very high and very low parathyroid hormone (PTH) levels are associated with the highest mortality rates in hemodialysis (HD) patients.

Paricalcitol Improves Survival Regardless of Baseline iPTH Levels

John Schieszer April 17, 2010

Use of paricalcitol for hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT) is associated with a significant improvement in survival independent of baseline levels of intact parathyroid hormone (iPTH) compared with patients who have untreated SHPT.

Cinacalcet Plus Low-Dose Vitamin D May Slow CAC Progression

John Schieszer April 17, 2010

Cinacalcet plus low-dose vitamin D therapy may improve biochemical control of secondary hyperparathyroidism (SHPT) and attenuate progression of coronary artery calcification (CAC) compared with flexible vitamin D therapy alone in hemodialysis (HD) patients.

Paricalcitol-Treated Hemodialysis Patients May Require Less Erythropoietin

John Schieszer April 16, 2010

Long-term hemodialysis (HD) patients who receive paricalcitol as treatment for secondary hyperparathyroidism (SHPT) may require less erythropoietin than those who receive no SHPT treatment, according to new data presented at the National Kidney Foundation's 2010 Spring Clinical Meetings.

Post-Dialysis Dosing of Cinacalcet May Address Noncompliance

John Schieszer April 16, 2010

Although daily dosing of cinacalcet may be an optimal treatment for secondary hyperparathyroidism (SHPT) compared with other dosing regimens, thrice-weekly post-dialysis dosing may be a viable option when daily dosing is ineffective because of patient noncompliance or other factors.

Low Vitamin D After Renal Transplantation May Be Underrecognized

John Schieszer April 16, 2010

Low serum 25-hydroxyvitamin D (25 D) levels may be playing a role in bone disease among renal transplant recipients, researchers reported here at the National Kidney Foundation's Spring Clinical Meetings.